Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden

References

• Mattisson C, Bogren M, Nettelbladt P, et al. First incidence depression in the Lundby Study: a comparison of the two time periods 1947–1972 and 1972–1997. J Affect Disord 2005;87:151-160
   PubMed Web of Science ®Google Scholar
• Nordström A, Bodlund O. Every third patient in primary care suffers from depression, anxiety or alcohol problems. Nord J Psychiatry 2008;62:250
   PubMed Web of Science ®Google Scholar
• Sobocki P, Lekander I, Borgstrom F, et al. The economic burden of depression in Sweden from 1997–2005. Eur Psychiatry 2007;22:146-152
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Hopkins HS. Assessing and treating depression in primary care medicine. Am J Med 2007;120:105-108
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157:1-45
   Google Scholar
• Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22:343–396. Epub 2008 Apr 15
   Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242
   PubMed Web of Science ®Google Scholar
• Ruhé HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006;67:1836-1855. Review
   Google Scholar
• Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008;63:699-704
   PubMed Web of Science ®Google Scholar
• Rush AJ. STAR*D: what have we learned?. Am J Psychiatry 2007;164:201-204
   PubMed Web of Science ®Google Scholar
• Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-350
   PubMed Web of Science ®Google Scholar
• Lam RW, Larsson Lönn S, Despiegel N. Escitalopram versus SNRIs as second-line treatment. Int J Psychiatry Clin Pract 2009;13(Suppl 1):35-36
   Google Scholar
• Armstrong EP, Skrepnek GH, Erder MH. Cost–utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2007;23:251-258
   PubMed Web of Science ®Google Scholar
• Khan A, Bose A, Alexopoulos CG, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Invest 2007;27:481-492
   PubMed Web of Science ®Google Scholar
• Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23:1605-1614
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-1196
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64
   PubMed Web of Science ®Google Scholar
• Wade AG, Milea D, Despiegel N, et al. A GPRD-based comparison of second-line antidepressant therapy with escitalopram and venlafaxine. Presented at the ISPOR 11th Annual European Congress, Athens, Greece, 8–11 November, 2008
   Google Scholar
• Wade AG, Milea D, Despiegel N, et al. A comparison of second-line antidepressant therapy with escitalopram and venlafaxine in the UK based on the General Practitioners Research Database. Clin Ther In press
   Google Scholar
• Benedict A, Arellano J, De Cock E, et al. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J Affect Disord 2009;120:94-104
   Google Scholar
• Sobocki P, Ekman M, Agren H, et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006;60:791-798
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-932
   PubMed Web of Science ®Google Scholar
• MEPS, 2003: Agency for Healthcare Research and Quality, Center for Cost and Financing Studies. MEPS HC-052. 2000 medical conditions, June 2003 [online]. Available from URL: http://www.meps.ahrq.gov/PUFFiles/H52/H52doc.htm [Accessed (2003) Nov 10]
   Google Scholar
• National Institute for Clinical Excellence: Guide to the Methods of Technology Appraisal, April 2004. Available from URL: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf [Accessed Aug 2009]
   Google Scholar
• Croom KF, Plosker GL. A pharmacoeconomic review of its use in depression. Pharmaeconomics 2003;21:1185-1209
   PubMed Web of Science ®Google Scholar
• Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007;61:702-710
   PubMed Web of Science ®Google Scholar
• Fernandez J-L, Montgomery S, François C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23:155-167
   PubMed Web of Science ®Google Scholar
• Malone DC. A budget-impact and cost-effectiveness model for second-line treatment of major depression. J Manag Care Pharm 2007;13(6SupplA):S8-18
   PubMedGoogle Scholar
• Wade AG, Fernandez JL, Francois C, et al. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Pharmaeconomics 2008;26:969-981
   PubMedGoogle Scholar